Kleter G E, Brouwer J T, Heijtink R A, Schalm S W, Quint W G
Department of Virology, Erasmus University Rotterdam, The Netherlands.
Antimicrob Agents Chemother. 1993 Mar;37(3):595-7. doi: 10.1128/AAC.37.3.595.
In 24 patients with hepatitic C virus (HCV) infection who participated in a randomized trial with alpha 2B interferon, HCV RNA analysis by the polymerase chain reaction with two separate primer sets was performed at weeks 0, 4, and 24 and during a follow-up period of 6 to 9 months. Prior to therapy all patients were HCV RNA positive. During therapy, HCV RNA decreased to an undetectable level (< 1 chimpanzee infectious dose per ml) in nine patients at week 4. After week 4, no additional cases of HCV RNA disappearance (< 1 chimpanzee infectious dose per ml) were observed. During follow-up, HCV RNA could not be detected in four of the six patients with a sustained alanine aminotransferase response. These results suggest the probable predictive value of HCV RNA levels for detecting the failure of therapy in an early stage of HCV infection.
24例丙型肝炎病毒（HCV）感染患者参与了α2B干扰素随机试验，在第0、4和24周以及6至9个月的随访期内，使用两组不同的引物对通过聚合酶链反应进行HCV RNA分析。治疗前所有患者HCV RNA均为阳性。治疗期间，9例患者在第4周时HCV RNA降至不可检测水平（<每毫升1个黑猩猩感染剂量）。第4周后，未观察到HCV RNA消失（<每毫升1个黑猩猩感染剂量）的新增病例。随访期间，6例丙氨酸转氨酶持续应答的患者中有4例未检测到HCV RNA。这些结果提示HCV RNA水平在HCV感染早期检测治疗失败方面可能具有预测价值。
